Curiosis, Inc.

Curiosis, Inc.

KKRX:494120
8,190.00
KRW
+240.00
(+3.02%)
-539.64EPS
198.76BMarket Cap
Dec 02Next Earn
2024 Y
2025 Y
TTM
Revenue per Share
751.39
558.55
578.28
Basic EPS, GAAP
-668.5
-601.5
-539.64
Free Cash Flow per Basic Share
-726.57
-738.53
-644.41
Dividend per Share
- -
- -
- -
Book Value per Share
762.04
1,851.33
1,619.95
Tangible Book Value per Share
744.16
1,836.45
1,592.44
Basic Weighted Avg Shares
7
13
15
Sales/Revenue/Turnover
5,415
7,303
8,452
Operating Margin (%)
-114.54
-103.05
-92.82
Depreciation Expense
1,039
965
1,043
Net Income, GAAP
-4,818
-7,864
-7,887
Effective Tax Rate (%)
- -
- -
- -
Profit Margin (%)
-88.97
-107.69
-93.32
Working Capital
7,679
25,293
20,008
LT Debt
854
725
895
Total Equity
9,709
28,201
24,720
Return on Invested Capital (%)
- -
- -
- -
Return on Capital (%)
- -
- -
- -
Return on Common Equity (%)
- -
-41.49
- -

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
2,477
2,477
2,689
LT Borrowings
598
498
498
LT Finance Leases
127
169
397
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
15
15
15
Market Capitalization
373,208
447,849
198,758

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
28,535
26,253
24,013
Cash, Cash Equivalents & STI
24,196
22,099
18,581
Accounts Receivable, Net
994
649
1,325
Inventories
2,604
2,771
3,484
Total Current Liabilities
3,242
3,227
4,005
Payables & Accruals
- -
- -
- -
ST Debt
2,477
2,477
2,689
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
190.48%
Free Cash Flow
- -
- -
84.41%
Net Income, GAAP
- -
- -
63.24%
Sales/Revenue/Turnover
- -
- -
34.86%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
5,415
2025
1,461
2,009
1,151
2,682
7,303
2026
1,146
3,473
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
-668.5
2025
-276.5
-105
-162.5
-148.29
-601.5
2026
-96.86
-136.5
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

CEO
Ho-Young Yoon
Full Time Employees
93
Sector
Health technology
Industry
Medical specialties
Address
Seoul South Korea
IPO Date
Nov 13, 2025
Business
Curiosis, Inc. is a South Korea-based life sciences technology company that develops, manufactures, and commercializes automated bio-imaging instruments, optical diagnostic equipment, and microfluidics-based cell analysis platforms for biomedical research and clinical diagnostics. The company operates within the laboratory instrumentation and life sciences tools sector, providing solutions optimized for cell biology, drug discovery, immunology, and regenerative medicine. Curiosis offers a systematic portfolio of laboratory systems and consumables, including automated live-cell imaging systems marketed under the Celloger brand, featuring the Celloger Mini, Celloger Mini Plus, Celloger Pro, and Celloger Stack, which provide real-time, time-lapse brightfield and dual-fluorescence microscopic observation inside standard incubators; automated cell counters and viability analyzers utilizing disposable microfluidic hemocytometers; precision-engineered microfluidic chips, counting chambers, and assay consumables for cellular analysis; and proprietary image acquisition and analysis software platforms supporting automated confluence assessment, fluorescent signal quantification, and kinetic cell tracking. The company targets academic research institutions, biotechnology and pharmaceutical enterprises, contract research organizations, and hospital laboratories throughout South Korea, North America, Europe, and the broader Asia-Pacific region. Founded in 2015 and headquartered in Seoul, South Korea, Curiosis, Inc. listed its shares on the Korea Exchange under the ticker 494120. In recent operational and strategic developments, the company completed its public listing on the KRX via a special purpose acquisition company merger, launched next-generation multi-position and multi-fluorescence live-cell imaging instruments, and expanded its international commercial infrastructure through strategic distribution partnerships across key European and North American life science markets.